Applicable provision of the Companies Act, 2013 with respect to corporate governance and the provisions of the SEBI (LODR) Regulations, 2015, as amended from time to time, will be applicable to our Company upon the listing of the Equity Shares with the Stock Exchanges in India.

Our Company is in compliance with the corporate governance code in accordance with Companies Act, 2013, SEBI (LODR) Regulations, 2015 and SEBI Regulations, as amended from time to time, particularly those relating to composition of Board of Directors and constitution of committees thereof. The corporate governance framework is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team and constitution of the Board Committees, as required under law.

Our Board has been constituted in compliance with the Companies Act and the SEBI Listing Regulations. The Board functions either as a full board, or through various committees constituted to oversee specific operational areas.

Composition of Board of Directors

Currently, the Board of Directors of our Company has an optimum combination of executive and non-executive Directors as envisaged in accordance with Companies Act, 2013 and SEBI (LODR) Regulations, 2015. Our Board has five Directors, comprising of one Managing Director, one Joint Managing Director, and three Non-Executive Independent Directors.

Our Company has constituted the following Committees in compliance with the corporate governance norms:
  1. Audit Committee;
  2. Nomination and Remuneration Committee;
  3. Stakeholders Relationship Committee;
  4. Corporate Social Responsibility Committee; and
  5. Sexual Harassment Committee.

Outlook On Exports Of Indian Pharmaceutical

  • India is the world’s largest provider of generic medicines; the country’s generic drugs  account for 20 per cent of global generic drug exports (in terms of volumes). Indian
    drugs are exported to more than 200 countries in the world, with the US as the key market.
  • Indian pharma companies are capitalising on export opportunities in regulated and semi-regulated markets.
  • Pharmaceutical exports from India reached US$ 17.27 billion in FY18 and US$ 10.80 billion in FY19 (up to October 2018). Pharmaceutical exports include bulk drugs, intermediates, drug formulations, biologicals, Ayush & herbal products and surgicals.
  • The US is the biggest export destination for Indian pharma product is the US. In FY18, 31 per cent of India’s pharma exports were to the North America, followed by 19.4 percent to Africa and 15.9 per cent to the European Union
Major Export Destinations in India’s Pharma Export in FY18 (%)

Pharmaceutical Exports from India (US$ billion)